Loading...
XSTO
VICO
Market cap256mUSD
Dec 05, Last price  
10.28SEK
1D
-0.77%
1Q
-15.04%
Jan 2017
-36.22%
IPO
94.88%
Name

Vicore Pharma Holding AB

Chart & Performance

D1W1MN
XSTO:VICO chart
P/E
—
P/S
22.05
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.25%
Rev. gr., 5y
-11.73%
Revenues
109m
3,3143,305,0001,571,000840,000852,000932,000508,00000000109,346,000
Net income
-169m
L-45.77%
-3,158-1,603,00013,687,000-4,570,000-6,652,000-12,855,000-21,681,000-93,084,000-146,862,000-296,481,000-288,422,000-310,942,000-168,634,000
CFO
-165m
L-33.91%
-1,669-1,793,000-2,825,000-3,682,000-7,251,000-7,705,000-33,036,000-86,999,000-119,935,000-265,171,000-299,919,000-249,583,000-164,946,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
URL
https://vicorepharma.com/
IPO date
Dec 10, 2015
Employees
23
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT